Radiopharm Theranostics (ASX:RAD) completed the preclinical package for its radiotherapeutic product 161 terbium-labeled RAD 402, or 161Tb-Rad 402, according to a Tuesday filing with the Australian bourse.

Preclinical toxicology studies showed no adverse effects, while biodistribution reports showed minimal uptake in the kidney and bone marrow with high-prostate cancer tumor targeting in mice models, the filing said.

The biopharmaceutical firm is expected to conduct its first-in-human trials for the product by the second half of 2025, per the filing.

Company shares slumped 17% in recent Tuesday trade.

Price (AUD): $0.03, Change: $-0.01, Percent Change: -17.07%